Daily Bulletin

New data independently confirms and extends laboratory findings and expands safety profile of ATH434-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

MELBOURNE, Australia and SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of...

Read more: New data independently confirms and extends laboratory findings and expands safety profile of...

More Articles ...

  1. Tile™ and Skullcandy Create Most Advanced True Wireless Finding Experience-PR Newswire APAC
  2. Trade360 Announces New Trading Platform-PR Newswire APAC
  3. Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC

Business News

Tips from Organisational Change Management Experts for Leading Successful Transitions

Corporate evolution has accelerated dramatically in today's volatile business environment, requiring leaders to develop sophisticated approaches to managing workforce transitions across technologica...

Daily Bulletin - avatar Daily Bulletin

Cross-Continental Collaboration: Nutifood and Viplus Dairy to Create Australian- Standard Premium Dairy Brand

Vietnam’s Nutifood has officially entered a strategic partnership with ViPlus Dairy, a heritage-rich dairy manufacturer with over 130 years of experience in Gippsland, Australia, to establish an int...

Daily Bulletin - avatar Daily Bulletin

Beyond the Marker: How Modern Whiteboards Drive Team Collaboration

In an age where flexibility and innovation define competitive advantage, the humble whiteboard has undergone a transformation. From static office fixture to dynamic collaboration hub, modern whiteboar...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals